Uréia

PreclinicalSmall molecule

UUniversity of Sao Paulo General Hospital

Uréia is one of 15 small molecule programs targeting Burning Mouth Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Burning Mouth SyndromeActive, not recruiting

Burning Mouth SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Burning Mouth Syndrome

#DrugCompanyPhaseTrials

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Approved

6 2

Cymbalta

Alnylam Pharmaceuticals

Phase 3

1 3

Lexapro

AbbVie

Phase 3

1 4

Celexa

AbbVie

Phase 3

1 5

Zoloft

VViatris Specialty LLC

Phase 3

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Phase 3

1 7

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 8

Western Medicine

PPeking Union Medical College Hospital

Phase 3

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

—10

Botulinum Neurotoxin Type a

DDeNova Research

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Burning Mouth Syndrome1 trial

The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study

Completed·UUniversity of Sao Paulo General Hospital·N/A·NCT01754740·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Uréia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Uréia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Uréia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Sao Paulo General Hospital

Uréia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Burning Mouth Syndrome1 trial

References

Drug Info

Quick Facts

Related News